Induced pluripotent stem cells: applications in regenerative medicine, disease modeling, and drug discovery by Vimal K. Singh et al.
REVIEW ARTICLE
published: 02 February 2015
doi: 10.3389/fcell.2015.00002
Induced pluripotent stem cells: applications in regenerative
medicine, disease modeling, and drug discovery
Vimal K. Singh1*, Manisha Kalsan2, Neeraj Kumar2, Abhishek Saini2 and Ramesh Chandra3
1 INSPIRE Faculty, Stem Cell Research Laboratory, Department of Biotechnology, Delhi Technological University, Delhi, India
2 Stem Cell Research Laboratory, Department of Biotechnology, Delhi Technological University, Delhi, India
3 B. R. Ambedkar Centre for Biomedical Research, University of Delhi, Delhi, India
Edited by:
Thimios Mitsiadis, University of
Zurich, Switzerland
Reviewed by:
Eumorphia Remboutsika,
Biomedical Sciences Research
Center “Alexander Fleming,” Greece
Marco Emilio Bianchi, Università Vita
Salute San Raffaele, Italy
Nicola Baldini, University of Bologna,
Italy
*Correspondence:
Vimal K. Singh, Stem Cell Research
Laboratory, Department of
Biotechnology, Delhi Technological
University, Shahbad Daulatpur,
Bawana Road, Delhi-110042, India
e-mail: vim_kissor@yahoo.co.in;
vimalkishorsingh@gmail.com;
vimalksingh@dce.ac.in
Recent progresses in the field of Induced Pluripotent Stem Cells (iPSCs) have opened
up many gateways for the research in therapeutics. iPSCs are the cells which are
reprogrammed from somatic cells using different transcription factors. iPSCs possess
unique properties of self renewal and differentiation to many types of cell lineage. Hence
could replace the use of embryonic stem cells (ESC), and may overcome the various
ethical issues regarding the use of embryos in research and clinics. Overwhelming
responses prompted worldwide by a large number of researchers about the use of
iPSCs evoked a large number of peple to establish more authentic methods for iPSC
generation. This would require understanding the underlying mechanism in a detailed
manner. There have been a large number of reports showing potential role of different
molecules as putative regulators of iPSC generating methods. The molecular mechanisms
that play role in reprogramming to generate iPSCs from different types of somatic cell
sources involves a plethora of molecules including miRNAs, DNA modifying agents (viz.
DNA methyl transferases), NANOG, etc. While promising a number of important roles in
various clinical/research studies, iPSCs could also be of great use in studying molecular
mechanism of many diseases. There are various diseases that have been modeled by
uing iPSCs for better understanding of their etiology which maybe further utilized for
developing putative treatments for these diseases. In addition, iPSCs are used for the
production of patient-specific cells which can be transplanted to the site of injury or the
site of tissue degeneration due to various disease conditions. The use of iPSCs may
eliminate the chances of immune rejection as patient specific cells may be used for
transplantation in various engraftment processes. Moreover, iPSC technology has been
employed in various diseases for disease modeling and gene therapy. The technique offers
benefits over other similar techniques such as animal models. Many toxic compounds
(different chemical compounds, pharmaceutical drugs, other hazardous chemicals, or
environmental conditions) which are encountered by humans and newly designed drugs
may be evaluated for toxicity and effects by using iPSCs. Thus, the applications of iPSCs
in regenerative medicine, disease modeling, and drug discovery are enormous and should
be explored in a more comprehensive manner.
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INTRODUCTION
Discovery of self-renewal by any living cell was one of the major
breakthrough reported by Till and McCulloch (1961) who while
subjecting the mice with lethal doses of radiation followed by
injection of bone marrow cells found that these cells formed
clumps due to cells cloned from them which was the main reason
of survival of the mice (Till and McCulloch, 1961). Later studies
defined their potential for differentiation into different cell types
and self-renewal without senescence, and termed as Stem Cells.
Stem cells can be defined on the basis of their origin and potency
into Adult Stem Cells and Embryonic Stem Cells (ESC), simi-
larly, considering their potency as the base of classification, stem
cells can be classified into unipotent, multipotent, oligopotent,
pluripotent, and totipotent (Lan et al., 2012). Totipotent are
those which can differentiate into embryonic as well as extra-
embryonic tissues such as the placenta. Pluripotent stem cells
are those which can differentiate into other cells of the adult
body. This property exists for only a specific time period of pre-
implantation development in the cells forming Inner Cell Mass
(ICM). As the cells differentiate into other cell lineages, their self
renewing potential decreases due to various epigenetic changes
which leads to the loss of pluripotency. Further research con-
ducted on human stem cells (HSCs) made burgeoning use of
human ESCs for which embryo needed to be isolated on regu-
lar basis that evoked several ethical issues among socio-research
communities. There have been efforts by different research groups
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to bypass these ethical/technical problems. Subsequent studies
demonstrated many advancements in the related techniques such
as cloning in frog (Gurdon, 1962), generation of mouse Stem
Cells (SCs) (Evans and Kaufman, 1981), cloning in sheep (Wilmut
et al., 1997), generation of HSCs (Thomson et al., 1998), and
development of Embryonic stem cell fusion technique (Tada et al.,
2001). These findings contributed greatly to the development of
cells that could eliminate ethical issues (Figure 1). However, the
major breakthrough came in 2006 when Takahashi and Yamanaka
introduced the concept of induced pluripotent stem cells (iPSCs)
by generating stem cells that were having properties relating
to ESCs. iPSCs were generated by using a combination of 4
reprogramming factors, including Oct4 (Octamer binding tran-
scription factor-4), Sox2 (Sex determining region Y)-box 2, Klf4
(Kruppel Like Factor-4), and c-Myc and were demonstrated both
self-renewing and differentiating like ESCs, and thus, could be
used as an alternative for hESCs in various clinics/research. Since
then, a number of different reprogramming factors/methods have
been established. iPSCs generation may employ combination
of different reprogramming factors, viz., a cocktail of various
reprogramming factors, direct use of proteins, miRNA, peptide
etc. Factors (LIN28 + Nanog, Esrrb, Pax5 shRNA, C/EBPa, p53
siRNA, UTF1, DNMT shRNA, Wnt3a, SV40 LT(T), hTERT) or
chemicals (BIX-01294, BayK8644, RG108, AZA, dexamethasone,
VPA, TSA, SAHA, PD025901 + CHIR99021(2i), A-83-01) have
been found which are able to replace one or the other reprogram-
ming factors from basal reprogramming factors or to enhance
the efficiency of reprogramming (Table 1) (Yu et al., 2007; Dimos
et al., 2008; Hanna et al., 2008; Huangfu et al., 2008a,b; Mali et al.,
2008;Marson et al., 2008;Mikkelsen et al., 2008; Park et al., 2008a;
Shi et al., 2008a,b; Silva et al., 2008; Zhao et al., 2008; Zhou et al.,
2008; Feng et al., 2009; Li et al., 2009; Fong et al., 2011).
Similarly, there have been significant advancements in meth-
ods/techniques employed to deliver these factors such as Nuclear
Transfer, Transcription Factors (Oct4, Sox2, Klf4 and c-Myc)
and different reprogramming technologies, including Integration
viral vectors and Integration free vectors (Plasmid DNA and
transferase, Viral vectors, and Excision of integrated transgenes)
(Hochedlinger and Jaenisch, 2002; Takahashi and Yamanaka,
2006a; Takahashi et al., 2006b; Yu et al., 2007; Stadtfeld et al.,
2008a,b,a,b; Fusaki et al., 2009; Gonzalez et al., 2009; Yusa
et al., 2009) (Table 2). The various sources, delivery meth-
ods and their cognate approaches with different combinations
of transcription factors differ significantly in their efficiency
(Tables 2, 3).
Since their discovery, iPSCs have been used in many research
and clinical studies including disease modeling, regenerative
medicine, and drug discovery/drug cytotoxicity studies. For disease
modeling, somatic cells possessing the characteristics of diseased
cells from patient are used for the generation of iPSCs and are
further utilized for studying the diseases. Similarly, iPSCs are
widely utilized for the regeneration of tissue-specific cells for the
transplantation to patients of various injuries or degenerative
diseases. Studies like drug discovery which implies screening of
small molecules, testing of toxicity for assessment of safety, have
successfully exploited iPSCs based technique. A large number of
reports have accumulated indicating a need for discussing various
apects of these techniques and their future perspectives in clini-
cal/research studies. This article focuses the importance of these
cells for therapeutics and research benefits in different biological
sciences.
REGULATORY FACTORS OF iPSCs GENERATION: AN
OVERVIEW
GENERATION OF iPSCs
Theoretically, iPSCs can be generated by using any somatic cell
by employing appropriate reprogramming factors and most con-
venient method for their introduction to somatic cells. iPSC
FIGURE 1 | Historical timeline showing events that led to the development of iPSCs and the recent advances that have occurred in the field.
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Table 1 | Many factors and chemicals are able to replace the basal transcriptions factors used for reprogramming (O- Oct4; S- Sox2; K- Klf4; M-
c-Myc; M*- N-Myc).
Factor/chemical Function Able to replace References
Nanog ESC-specific transcription factor Together with Lin28, able of replacing K andM Yu et al., 2007
Lin28 ESC-specific RNA-binding protein Together with Nanog, able of replacing K andM Yu et al., 2007
Esrrb Orphan nuclear receptor K Feng et al., 2009
SV40 LT (T) SV40 large T antigen used for cell transformation K; M* and Lin28, Nanog Mali et al., 2008
BIX-01294 Inhibitor of G9a histone methyltransferase S, O Shi et al., 2008a,b
VPA Inhibitor of histone deacetylase K andM Huangfu et al., 2008a
Table 2 | Different delivery methods for transfer of different combinations of transcription factors have different efficiencies of reprogramming
(O- Oct4; S- Sox2; K- Klf4; M- c-Myc).
Reprogramming Factors Cell type Efficiency % References
Integrating
methods
Retroviral transduction OSKM Mouse fibroblast 0.001–1 Takahashi and Yamanaka, 2006a
OSK + VPA Neonatal 1 Huangfu et al., 2008a
Lentiviral OSKM Human fibroblast 0.1–1 Yu et al., 2007
OK +
parnate +
CHIR99021
Neonatal 0.02 Li et al., 2009
Inducible lentiviral OSKM Human fibroblast 0.1–2 Maherali et al., 2008
Non-
integrating
methods
Sendai virus OSKM Human fibroblast ∼0.1 Fusaki et al., 2009
Adeno viral transduction OSKM Mouse fibroblast ∼0.001 Stadtfeld et al., 2008a
Plasmid DNA transfer OSK Fibroblast 0.00 Okita et al., 2008
lox p lentivirus OSKM Fibroblast 0.1–1 Somers et al., 2010
PiggyBAC OSKM Fibroblast 0.01 Woltjen et al., 2009
Polyarginine tagged polypeptide OSKM Neonatal fibroblast 0.00 Kim et al., 2009b
RNA modified synthetic mRNA OSKM Human fibroblast 4.40 Warren et al., 2010
generation is reported by using cells from different sources such
as fibroblasts, cord blood, peripheral blood (Table 1). There are
large numbers of reports showing the whole process in a detailed
manner that can be summarized in three major steps—(i)
establishment of initial cell culture, (ii) induction of iPSCs and,
(iii) characterization and expansion of iPSCs (Figure 2). Firstly,
the source cells are isolated and cultured. The reprogramming
factors are then introduced into those cultured cells. There
are two types of methods for the introduction of reprogram-
ming factors- Integrating Systems (retroviral, lentiviral, inducible
lentiviral) and Non-Integrating Methods [non-intergrating viral
vectors (sendai virus, adeno virus), plasmid DNA transfer, trans-
genes, recombinant proteins, synthetic mRNA] (Table 2). These
transfected cells are incubated on feeder layers (a number of
cells have been demonstrated as feeder cells, example., fibrob-
lasts, keratinocytes) under appropriate media conditions and
after the expression of these reprogramming factors, generation of
iPSCs occurs. The cultured iPSC colonies can be characterized by
different morphological and physiochemical methods. The mor-
phological examination of iPSCs can be done on the basis of
round shape, large nucleolus, and scant cytoplasm of iPSCs as
similar to ESCs (Thomson et al., 1998). Reprogrammed colonies
are tightly packed, sharp edged, flat, mitotically very active due
to the possession of property of self renewal. Though it is hard
to define iPSCs solely on the basis of their morphology, these
characteristics give a quick idea about their states. Further, iPSCs
may be defined on the basis of expression of different cell surface
proteins (SSEA-4, alkaline phosphatase) and transcription factors
Oct4, Sox2, Nanog which can also be used for the characterization
(Adewumi et al., 2007). Figure 3 describes the necessary require-
ments (Yamanaka’s cocktail, alternative factors or chemicals for
the replacement of one or more basal reprogramming factors
enhancement of efficiency of generation) for the generation of
iPSCs.
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Table 3 | Different cell sources and different combinations of
reprogramming factors have been used by different groups for
reprogramming to iPSCs (O- Oct4; S- Sox2; K- Klf4; M- c-Myc; N-
Nanog, L- Lin28).
Type of cells Reprogramming References
factors
Fibroblast OSKM Takahashi and Yamanaka,
2006a
OSLN Yu et al., 2007
Keratinocytes OSKM Aasen et al., 2008
Cord blood endothelial
cells
OSLN Haase et al., 2009
Cord blood stem cells OSKM Ye et al., 2009
Neural stem cells O Kim et al., 2009a
Melanocytes OSKM Utikal et al., 2009
Amniotic cells OSKM Li et al., 2009
Adipose derived stem
cells
OSKM Sugii et al., 2010
Hepatocytes OSKM Liu et al., 2010
Circulating T cells OSKM Seki et al., 2010
Astrocytes OSKM Ruiz et al., 2010
Peripheral blood OSKM Kunisato et al., 2011
Kidney mesangial cells OSKM Song et al., 2011
Urine cells OS Zhou et al., 2012
DIFFERENT FACTORS THAT PLAY ROLE IN THE GENERATION OF iPSCs
As discussed above, the generation of iPSCs from somatic cells
requires the introduction of reprogramming factors into the
somatic cells. This can be done by two types of methods—
Integrating Viral Vector Systems and Non-Integrating Systems.
Integrating methods are those in which the viral vector gets
integrated into the host cell genome. The use of retrovirus and
lentivirus comes under this category (Takahashi et al., 2006b;
Brambrink et al., 2008; Stadtfeld et al., 2008a,b). This method
has a high efficiency but it poses the risks of cancer formation
and hence, different approaches have also been worked on. Non-
Integrating methods are those in which no integration in host cell
genome occurs. Different approaches such as viral vectors (Adeno
virus and Sendai virus), Plasmid DNA, and the use of RNA and
proteins come under this category. Adeno virus (dsDNA) and
Sendai virus (RNA) are non-integrating viral vectors which have
been used in iPSC generation (Takahashi et al., 2006b; Stadtfeld
et al., 2008a; Fusaki et al., 2009). Plasmids such as oriP/EBNA1
(derived from Epstein-bar virus), containing reprogramming fac-
tors has been used for reprogramming, but the efficiency was
found to be low (Yu et al., 2009). Direct delivery of reprogram-
ming proteins has also been carried out by fusing them with a cell
penetrating peptide (Kim et al., 2009b). Yashioka et al. used a dif-
ferent approach using a single self replicating RNA replicon which
expressed high levels of Yamanaka’s factors for transfection into
fibroblasts to be reprogrammed into iPSCs and found the iPSCs
to be having all properties of pluripotent stem cells (Yoshioka
et al., 2013).
Once the reprogramming factors are delivered to the somatic
cells, they come into play for transforming those somatic cells into
iPSCs. Not only they have their individual roles, but they interact
with each other complementarily.
APPLICATIONS OF iPSCs
The treatment of many diseases is difficult because of the lack
of information about the mechanisms that play a role in the
disease progression. For this reason, diseases need to be mod-
eled so that treatment could be developed aiming the main
cause of the disease. There are a large number of disease test-
ing models which have developed during previous era. Some
of them are capable of mimicking human cellular microenvi-
ronment and metabolism to some extent. Many animal mod-
els such as rat, mice, dogs monkey, dog, and primates have
been used for disease modeling. However, the use of animals
as disease models is limited due to existing variability in the
genetic make-up of them that is highly responsible for the bio-
logical functions and hence differences are exhibited while com-
pared with human individuals. Secondly, the problem further gets
complicated when the individuals are of two different species.
Different species have different genetic makeup and hence dif-
ferent proteins. And thus, none of the animal model is able to
fully mimick the human cell microenvironment. So, a differ-
ent approach which can provide the same environment as in
human cells is required and iPSCs pose to be a good alterna-
tive with some advantages as well. In case of iPSCs, there is
no need of proliferation again and again, and, their derivatives
are functional in-vitro as well as in-vivo after transplantation.
Induced pluripotent stem cells are widely used in therapeutics
for disease modeling, regenerative medicine, and drug discovery
(Figure 4).
DISEASE MODELING
The use of iPSCs for disease modeling is based on the fact that
these cells are capable of self renewing and that these cells can
differentiate into all types of cells of the human body which
can be utilized for the preparation of different disease models
to study those diseases. Moreover, a patient specific iPSC could
be of enormous use as far as development of specific therapeu-
tics regimen/drug is concerned. By combining 3D culture with
extracellular matrix proteins, in-vivo microenvironment can be
mimicked. Lee et al. used iPSCs for the modeling of pathogene-
sis in Familial Dysautonomia (Lee et al., 2009). Since then, there
have been many cases in which iPSCs have helped out in studying
various mechanisms that play role in different diseases, a few have
been described below.
Moad et al. used human prostate and urinary tract cells for
the formation of iPSCs and further for studying the mechanisms
that regulate the differentiation of prostate and urinary tract cells.
With their study, they reported the first successful reprogramming
of bladder, prostate and ureter stromal fibroblasts into a pluripo-
tent state and concluded that iPSCs generated from prostate and
urinary tract had better efficiency of differentiation to cells of
prostate and urinary tract as compared to iPSCs derived from skin
fibroblasts which showed that organ of origin plays an important
role in terms of efficiency of differentiation (Moad et al., 2013).
Various types of diseases which are caused by some defi-
ciency have been studied by using iPSCs. Park et al. used
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FIGURE 2 | An overview of the methodology for the generation of
iPSCs. (1) Establishment of culture: the source cells are cultured for
further use as host cells for the delivery of reprogramming proteins. (2)
The cultured source cells are then transfected with the four factors from
Yamanaka’s cocktail and incubated on feeder layers that provide the
nourishment to host cells and are responsible for the formation of extra
cellular matrix, under suitable conditions of media. Two types of methods
for the delivery of reprogramming factors into the somatic cells can be
used- Integrating viral vector systems and Non-Integrating methods. (3)
After the formation of iPSCs, they are characterized by different
morphological and physicochemical analyses, which is followed by the
expansion of iPSCs.
FIGURE 3 | Introduction of the four transcription factors (Oct-4, Sox-2,
Klf-4, and c-Myc) leads to reprogramming of a somatic cell to an Induced
Pluripotent Stem Cell (iPSC) which can further differentiate into different
types of cells. Many factors or chemicals are able to replace one of the
factors from the basic four factors required for reprogramming, and for the
enhancement many other small molecule chemicals or factor are also used.
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FIGURE 4 | There are many applications of iPSCs in the fields of gene
therapy, disease modeling and drug discovery. Somatic cells from the
patient are used for the generation of diseased iPSCs. These diseased iPSCs
may be repaired by Gene Therapy and further used for the generation of
healthy somatic cells to be transplanted to the patient, or they may be used
to produce unrepaired somatic cells for disease modeling or drug screening.
iPSCs from patients of various diseases like Adenosine Deaminase
Deficiency-related Severe Combined ImmunoDeficiency (ADA-
SCID), Shwachman-Bodian-Diamond syndrome (SBDS), Gaucher
disease (GD) type III for the study of disease models and drug
discovery. They used dermal fibroblasts or bone-marrow derived
mesenchymal stem cells for the generation of human iPSCs by
the transduction of all four or three (excluding c-Myc) tran-
scription factors. It was found from their study that ADA-SCID,
SBDS, and Gaucher’s disease type III are inherited in a classical
Mendelian Inheritance manner like congenital disorders which
are autosomal recessive. These diseases were shown to be caused
by point mutations in those genes which were vital for normal
hematopoiesis and immunological function. They also reported
the point mutations in ADA-SCID, SBDS, and GD type III.
They also studied Duchenne (DMD) and Becker muscular dys-
trophy (BMD), Parkinson disease (PD), Huntington disease (HD),
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juvenile-onset, type 1 diabetes mellitus (JDM), Down syndrome
(DS) /trisomy 21 and the carrier state of Lesch-Nyhan syndrome
(Park et al., 2008b).
There are many syndromes which are caused by the existence
of one or more extra copies of a chromosome. Downs syndrome
is one such example. Briggs et al. used iPSCs for the identi-
fication of molecular networks that drive the different aspects
related to pathogenesis in Down’s Syndrome. iPSCs in combi-
nation with microarray and RNA sequencing technology, can
be used to generate phenotype-genotype maps of complex dis-
eases by linking various defects with phenotypes, like in Down’s
Syndrome using Chromosome engineering of Down Syndrome-
iPSCs (Briggs et al., 2013).
Neurogenerative diseases have also been studied using iPSCs
as disease models. Parkinson’s Disease (PD) is a very common
neurodegenerative disease, in which, dopaminergic neurons of
substantia nigra (a structure in mid brain) get lost and forma-
tion of Lewy’s bodies (inclusions in the cytoplasm of neurons
all over the body) occurs. Treatment of this disease had not
been possible due to the reason that by the time, PD gets clin-
ically manifested, the neurons have already lost, which makes
it very difficult to be able to study the underlying mechanisms
of PD so as to develop a treatment of it. In such a situation,
iPSCs can be used and experiments have also been carried out
in this aspect. Nguyen et al. studied G2019S mutation in LRRK2
(Leucine Rich Repeat Kinase2) gene. This mutation has been
reported in cases of sporadic and familial PD. Fibroblasts from
a 60-year old female homologous for G2019S mutation were used
as a source for the generation of iPSCs. Retrovirus was used
for the transduction of Oct4, Sox2, and Klf4 into the fibrob-
lasts, which after 2 months of transfection developed 3 colonies
of human ESC, which were analyzed and found out to be simi-
lar to hESCs and wild type iPSCs. For differentiation of G2019S
iPSCs to dopaminergic neurons, a combination of mib-brain
selective patterning factors, sonic hedgehog (SHH) (induces the
differentiation of dopaminergic neurons in substantia nigra), and
Fibroblast growth factor 8 beta (FGF8b) [induces the develop-
ment of cerebellum by the activation of Ras-extracellular signal-
regulated kinase (ERK) pathway] and small molecules was used.
The neurons generated by this method were functionally active
and were found to be able to form active neural networks.
The findings suggested LRRK2 to be having an important role
in survival of neurons and disruption of which can cause PD.
(Hurtado-Lorenzo et al., 2004; Sato et al., 2004; Nguyen et al.,
2011). Similarly, a different group has also worked for the gen-
eration of iPSCs in PD. Devine et al. developed iPSCs from
fibroblasts taken from a PD affected person possessing triplication
of Synuclein gene by the transduction of four basic transcrip-
tion factors. These iPSCs were then directed to differentiate into
dopaminergic neurons in vitro for the study of PD (Devine et al.,
2011).
These findings from modeling different diseases (mutations
which are causing them, the pathological phenotypes caused by
defects in various networks, genes playing an important role)
help out in knowing the molecular mechanisms underlying the
disease better, which ultimately carries the work forward to know-
ing the disease better for the development of a treatment. This
is evident from burgeoning reports on use of IPSc for the the
purpose of disease modeling (Table 4). However, the technique
suffers from various inherited risks and limitations as discussed
ahead.
REGENERATIVE MEDICINE
In regenerative medicine the injured or degenerated tissues are
repaired by the generation of those tissues with the help of iPSCs
in labs and then transplanting them to the site of injury or
degeneration. Important issues associated with gene therapy are
availability of tissue or organ and immunorejection. It is quite
often that patients die because of the non-availability of donors
which is a result of the fact that the population is non-aware of
the scarcity of donors and the ever inceasing need of organs due
to accidents and degenerative diseases. Also, a patient can only be
transplated with the cells, tissues, or organs from the person who
does not have any disease and whose physiological profilematches
with the patient. Keeping these risks in mind, various tests are
conducted before transplating tissues or organs into the patient’s
body. The use of iPSCs offers a good approach for these treat-
ments as the cells that will be transplanted to patient’s body will be
differentiated from the repaired iPSCs generated from the somatic
cells from patient’s own body. iPSCs have been used in treating
a number of injuries and degenerative diseases. A comprehen-
sive detail of all those would be beyond the scope of this article,
however, major arguments are discussed below. Different injuries
as a result of human activities, accidents or natural calamities
can also be treated by the gene therapy utilizing iPSCs. The
various conditions that can be treated are Hematopoietic dis-
orders, Musculoskeletal injury, Spinal cord injury, liver damage
by the generation of specific cells with the help of iPSCs (Liu
et al., 2011b; Nori et al., 2011; Tan et al., 2012; Suzuki et al.,
2013).
Other than accidental injuries, diseases can also be treated with
the help of iPSCs. Kazuki et al. corrected the genetic deficiency
in iPSCs from a human Duchhene Muscular Dystrophy (DMD)
patient. They used Human Artificial Chromosome (HAC) for
the expression of complete sequence of Dystrophin (DYS). They
used fibroblasts from the DMD patient for the generation of
iPSCs. HAC was used for the correction in the deletion or
mutation in the Dystrophin gene present in iPSCs by trans-
fer of DYS-HAC (complete genomic sequence of dystrophin in
HAC) using Microcell-mediated chromosome transfer (MMCT)
(Kazuki et al., 2009). MMCT is a technique in which micro cells
containing few chromosomes are fused with whole cells (Doherty
and Fisher, 2003).
iPSCS can also be used in cases of hepatocytes where loss
of function of hepatocytes in culture and limited organ avail-
ability act as obstacles when fetal or adult progenitors are used
for the development of hepatocytes. This lead to making use
of iPScs for the generation of hepatocytes for various liver
problems.
Recently, there are accumulating data on the use of iPSC for ex-
vivo blood expansion of various blood components. They can be
used for the generation of Red Blood Cells (RBCs) which could
be utilized for the generation of blood that is required over the
globe for the purpose of treatment of various damages or diseases.
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There are various techniques by which we can use ESCs/iPSCs for
the production of RBCs (Lim et al., 2013).
iPSCs can also be used for the generation of various cells which
can help in the repairmen of many tissues, for example, car-
diovascular cells for the repairment of heart valves, vessels and
ischemic tissues, but are limitations like safe delivery, post treat-
ment adverse effects and standardization of protocols to generate
large amounts of pure good quality cells. These obstacles once
overcome, offer great opportunities for the applications of iPSCs
for generating cardiovascular cells and studying corresponding
diseases (Laflamme et al., 2007; Cao et al., 2008; Levenberg et al.,
2010).
Various degenerative diseases in which cells death causes many
symptoms have been treated by gene therapy using iPSCs. One
such case is Retinitis pigmentosa (RP) where eye’s retina degener-
ation causes impaired vision. For the treatment of RP, iPSCs were
generated from the patient suffering with the disease which were
then showed to differentiate into rod photoreceptor cells (Yoshida
et al., 2014). The differentiation of iPSCs to Retinal pigmented
epithelium is proved to be beneficial for patients of Retinal
Pigmentosa and Age-related Macular Degeneration (AMD) (Li
et al., 2012).
Gene therapy using iPSCs has also been used to treat various
primary immunodeficiencies like Chronic Granulomatous disor-
der (CGD), an autosomal recessive or X-linked disorder which
affects the function of neutrophils, andWiskott–Aldrich syndrome
(WAS), X-linked deficiency caused by mutation in WAS gene
encodingWAS protein (WASp) which is an actin cytoskeletol reg-
ulator in hematopoietic lineage (Klein et al., 2003; Jiang et al.,
2012).
The technology of genome editing or genome engineer-
ing, which includes the use of different genome editing tech-
nologies like Zinc Finger Nucleases (ZFNs), Transcription
Activators like effector nucleases (TALENs), CRISPR/Cas systems,
Meganucleases, Adeno-associated viruses, and adenoviruses,
offers an opportunity for the efficient introduction of various
insertions or deletions that range from single nucleotides to inser-
tion/deletion of whole genes which has a capability of taking
disease modeling to new heights (Suzuki et al., 2008; Grizot et al.,
2009; Hockemeyer et al., 2009, 2011; Khan et al., 2010). Choi et al.
reported the gene correction in alpha 1 anti trypsin (AAT) defi-
ciency by the use of TALENs. A pair of TALEN expression vectors
was constructed. This construct recognized the sequences flank-
ing the Z mutation of the AAT gene. After co-nucleofection of
targeting vector and TALEN expression vector was carried out,
PCR and Southern blot was done. The results showed a highly
efficient and simultaneous targeting of both alleles (Choi et al.,
2013).
Once the specific cells are formed they can be transplanted to
the specific site, in case of degenerative diseases, for the cure of
the disease. And, in case where diseased cells which possess some
mutation, the mutation is first corrected to form normal iPSCs
and then these iPSCs are differentiated into specific cell types by
providing the specific conditions required for the development of
those cells. These repaired cells can then be transplanted into the
body of the organism from which the cells for the generation of
iPSCs were isolated.
DRUG DISCOVERY AND CYTOTOXICITY STUDIES
Another important role offered by the use of iPSCs based
methodology is their complementarity to drug discovery or pre-
diction of toxicity via animal models. Animals or in-vitro ani-
mal derived cells are used as testing systems butare limited by
their inability to to replicate the “exact” human physiological
conditions and related phenotypic attributions. Sometimes, the
benefits demonstrated in the animal models do not come out
to be beneficial in humans, for example, the SOD (superoxi-
dase dimutase) gene associated with ALS (Amyotrophic Lateral
Sclerosis) allowed the identification of Vitamin E and Creatine
to be relievers of the diseased phenotype which failed to cause
any improvements in humans (Desnuelle et al., 2001; Groeneveld
et al., 2003; Shefner et al., 2004). And also, animal models are not
good testing models for drug toxicity as a chemical may be toxic
to an animal but may not be toxic to a different animal. For car-
cinogenic agents as well, different agents pose different levels of
carcinogenicity in different animals, for example, formaldehyde
is more carcinogenic to rats as compared to mice (Kerns et al.,
1983). Finally, a newly discovered drug or therapy must be tested
on human cells or human test models itself. These reasons make
it more important to be able to use the systems closer to humans.
Moreover, these studies need to be done in a system where the
results could be directly extrapolated to humans. These stud-
ies include steps such as prediction/identification of a potential
drug molecule followed by its synthesis, generation of iPSCs, their
differentiation to specific somatic cells, and testing for toxic or
non-toxic effects of the synthesized drug on the somatic cells. For
toxicity studies, iPSCs from normal and diseased cells are used to
generate neurons, hepatocytes, cardiomyocytes etc. Toxicity and
potential side-effects are often most common cause to rule out
most of the therapeutic molecules.
There is a long pipeline between the time when a hit is identi-
fied and the time when it reaches the market. Before using drugs
on humans, their toxic effects must be properly evaluated for
a safe administration of those drugs which is very costly. Only
10% of the drugs that enter clinical trials are able to reach mar-
ket approval stage. The cost of developing a drug is increasing
with the estimated cost of whole process being US $1.2–1.7 billion
per drug compound (Kaitin, 2008; Sollano et al., 2008; Gunaseeli
et al., 2010). The development of 30% of the medicines was
abandoned because of lack of efficacy and 30% due to concerns
associated with safety (cardiotoxicity, hepatotoxicity) (Laustriat
et al., 2010). The blocking of human ether-a-go-go related gene
1 (hERG1) channel by drug is associated with longer duration of
ventricular repolarization which causes long QT syndrome. The
response of iPSC-derived cardiomyocytes have been reported in
response of cardiac and non-cardiac drugs in terms of electro-
physiological capacity (Tanaka et al., 2009; Yokoo et al., 2009;
Asai et al., 2010; Yoshida and Yamanaka, 2010). The generation
of functional hepatocytes using iPSCs has also been reported
(Sullivan et al., 2010). Due to lack in early detection of drug
toxicity in human tissues, the process becomes more costly and
extensively time consuming. Development of toxicity models that
predict more accurately before clinical trials may help to reduce
costs by demonstrating cardiotoxicity or hepatotoxicity caused by
the drugs much before they reach clinical trials; reducing the time
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taken for clinical trials of the drugs which will fail due to cyto-
toxicity in the later stages of trials. iPSCs have been explored by
many research groups in order to identify compounds which are
toxic or pose side-effects. The use of iPSCs offer better alterna-
tive to conventional tests of toxicology and drug research and
offer better chemical safety assessment as they provide a more
similar environment to human physiological conditions than is
provided by conventional testing systems which make use of ani-
mals. For example, iPSCs have been used to establish test systems
for cytotoxicity–cardiotoxicity, hepatotoxicity, and embryotoxic-
ity testing (Kimmel and Young, 1983; Seiler et al., 2004).
iPSCs have the potential of providing native cells for splic-
ing and post translational modifications that does not come with
the small molecule screening systems using purified protein or
recombinant cell lines used for the over-expression of the protein
of interest which has aided in the process of drug screening. The
use of iPSCs in drug screening has also been reported. Stem Cells
enable the identification of molecules therapeutically useful and
able to modulate the behavior of tumorigenic and normal stem
cells. But as the use of ESC is limited because of the concerned
ethical issues, iPSCs (normal and tumorigenic) can be used as an
alternative.
McNeisch et al. used neurons that were expressing a-amino- 3-
hydroxyl-5-methyl-4-isoxazoleproprionate (AMPA) subtype glu-
tamate receptors using mouse iPSCs and used them for the
identification of small molecule AMPA potentiators (McNeish
et al., 2010). Choi et al. used hepatic cells derived from iPSCs gen-
erated from patients with alpha-1 anti-trypsin deficiency for the
screening of 3131 compounds of Johns Hopkins Drug Library.
After immunofluorescence, total AAT fluorescence intensity was
measured for each well. Out of 262 compounds which inhib-
ited the accumulation of AAT by more than 50%, 43 compounds
after literature survey were found to be FDA approved, clinically
used internationally, and exerting no major side effect. These
compounds were further tested by using four different lines of
AAT- deficiency iPSCs and final 5 hits, which gave consistent
results in all the four iPSC lines were selected (Choi et al., 2013).
iPSCs also help in studying ADME (Absorption, Distribution,
Metabolism, Excretion) properties of drugs which has highly
speeded up drug discovery and development (Bahadduri et al.,
2010).
ADVANTAGES OF iPSC TECHNOLOGY
iPSCs offer various advantages as compared with gene therapy
by the use of nuclear transfer or Embryonic Cell mediated gene
therapy (Kazuki et al., 2009).
THE ETHICAL ISSUES ARE ELIMITED BY THE USE OF iPSCs
The use of ESCs in research is laden with ethical issues regard-
ing personhood, justice toward humankind and human dignity
that are associated with the use of human life in its earliest
form, the embryo. Additional concerns that surround the use of
ESCs are informed consent, improper incentives, and health and
safety concerns of the women donating eggs for the generation
of embryos by in-vitro fertilization. iPSCs have solved the contro-
versy over the destruction of embryos associated with the use of
ESCs in research.
REDUCED CHANCES OF IMMUNOREJECTION
iPSCs are generated from the somatic cells of one’s own body
and hence there is no risk of immunorejection of these autolo-
gous cells. Guha et al. differentiated mouse iPSCs into embryoid
bodies and different tissue specific cells. After the transplanta-
tion of these iPSC derived EBs or tissue specific cells, no evidence
of increased Tcell proliferation or an antigen- specific secondary
immune response was found (Guha et al., 2013).
THROUGHPUT SCREENING FOR PREDICTING TOXICITY/THERAPEUTIC
RESPONSES OF NEWLY DEVELOPED DRUGS
The concept of using iPSCs to predict toxicology and therapeutic
responses of drugs in based on the property of iPSCs to con-
tinuously self renew which make it possible to generate libraries
and their ability to give rise to all types of body cells make them
suitable to be used for prediction of toxicity and possible side
effects of newly developed drugs in different body cells (Wobus
and Loser, 2011).
LOWERING THE OVERALL COST AND RISK OF CLINICAL TRIALS
For every new drug to reach market, around 5000–10,000 com-
pounds need to be tested during preclinical trials. Therefore,
any strategy which standardizes the prediction of toxicity would
impact the cost. Many drugs fail after Phase III, for example BMS-
094 (hepatitis C drug) failed after death of a patient. The cost
used for the clinical trials could be reduced by using iPSCs to pro-
vide the toxicity details of the drug by different cytotoxicity assays.
Much of the cost for preclinical testing is due to the requirement
of animal models for estimation of bioavailability of new drug.
As animal models do not mimic the microenvironment of the
human cells fully, the use of iPSCs for these tests may cut the cost
associated with providing animal models which will ultimately
decrease the overall costs of the clinical trials.
DEVELOPMENT OF A PERSONALIZED APPROACH FOR
ADMINISTRATION OF DRUGS
As, iPSCs are derived from individual patients, these offer scien-
tists an opportunity for modeling diseases on a patient-by-patient
basis. This enables screening the genomic differences between
individuals that may help in the progression of disease, and the
screening of pharmacological agents to find the ideal one for each
individual (Chun et al., 2011).
GENE TARGETING AND CORRECTION TECHNOLOGIES (GENE THERAPY)
Reprogramming of somatic cells from any genetic background to
iPSCs has allowed the generation of cell lines possessing disease-
causing mutations. The ability of modifying the specific sites
in a genome for altering the genes of interest becomes highly
important here. To realize the full potential of iPScs, methods for
efficient genetic modifications are required.
FOR DISEASE MODELING, THE PHENOTYPES NEED TO BE CONSISTENT
EVERY TIME, WHICH IS A POSSIBILITY IN CASE OF iPSCs
Many research groups have modeled various diseases using iPSCs
and the cell lines developed were found to be consistent pheno-
typically. Fong et al. developed Tauopathy derived iPSCs carrying
a TAU-A152T mutation. The phenotypes observed in the cells
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from iPSCs were consistent with those in patients with the muta-
tion (Fong et al., 2013).
LIMITATIONS AND/OR RISKS ASSOCIATED WITH THE USE
OF iPSCs IC CLINICS
There are some limitations/disadvantages associated with iPSCs
as well. Generation of iPSCs make use of retroviral or lentiviral
systems, so, it needs to be concerned if the viral systems get incor-
porated with the host genome. The genetic material inserted via
retroviral vectors may randomly integrate into the genome of the
host which can cause genetic aberration and teratoma formation
(Howe et al., 2008). The transcription of the transgenes inserted
via vector systems may resume in the cells that have been formed
by the differentiation of iPSCs (Okita et al., 2007). The assess-
ment also becomes complex as it depends on number of variables,
like small molecules for the enhancement of iPSCs production
are used or not, whether the factors used for reprogramming
are contained in single vectors or multiple vectors, and which
source has been used for the generation of iPSCs, contribute to
the differences in the epigenome, genotype, and phenotype of the
iPSCs produced which make it difficult to determine whether the
problems occurred due to the technology or the reprogramming
method(s) (Howe et al., 2008; Li et al., 2011). It is possible to use
iPSCs for modeling of the diseases which have a phenotype and
are monogenic but in case of complex diseases the role of genetic
and epigenetic factors is uncertain which makes modeling of dis-
ease a tough job. It is not possible for iPSCs tomodel every disease
successfully, hence, it should be noted if the iPSCs derivatives are
getting properly matured to the cells of interest or not in order to
know if they are suitable to be used for the purpose of our interest
or not. The altered expressions of the basal reprogramming fac-
tors has also been reported to cause diseases. The overexpression
of Oct4 may lead to epithelial cell dysplasia (Hochedlinger et al.,
2005). The aberrant expression of Sox2 has been reported to
cause mucinous colon carcinoma (Park et al., 2008c). Klf4 has
role in the formation of breast tumors (Ghaleb et al., 2005). c-
Myc plays an important role in the formation of around 70% of
human cancers (Kuttler and Mai, 2006). For this reason, retro-
viral introduction of c-Myc is also advised to be avoided for use
in clinical applications (Okita et al., 2007). Zhang et al. reported
that out of 593 genes that express in iPSCs, 209 genes were found
to express in cancer tissues and tumor cells. Five oncogenes were
found to overexpress in iPSCs whereas the oncogene RAB25 was
found to express in cells derived from iPSCs (Zhang et al., 2012).
RAB25 (member of RAS protein family) plays an important role
in survival of cancer cells (Cheng et al., 2013). The different pros
and cons of the use of iPSCs in different applications has been
mentioned in Table 5.
QUALITY CONTROL TESTING OF iPSCs
There are many things which need to be considered before
using iPSCs clinically for regenerative medicine. The manufac-
ture of clinical grade iPSCs demand quality control at different
levels of the manufacturing process. Firstly, it is important to
decide whether the therapy would be autologous or allogeneic.
Autologous therapy should be such that it is able to manage
the differences in the patient in terms of age, health and gen-
der which could affect the quality, consistency and safety of the
final product. It requires long term study of the increased risk of
tumor formation as the patient would not be expected to have
any immune response. The alternative, allogeneic therapy offer
well-characterized cell banks for therapeutics to be established.
Donors need to meet strict eligibility requirements and the donor
must be aware of the use and testing of his sample and that the
Table 5 | The pros and cons associated with the use of iPSCs.
Pros Cons
Due to characteristics of
iPSCs
Eliminates ethical issues Premature aging
Reduced chances of immunorejection (Guha et al., 2013) High rate of apoptosis
Reduced risks of clinical trials Low level DNA damage repair (Zhang et al., 2012)
Consistent phenotypes for disease modeling (Fong et al.,
2013)
Sensitive to ionizing radiation (Zhang et al., 2013)
Differentiation to any cell type Low rate of reprogramming
Due to technology of
development
Continuous cell supply Insertional mutagenesis (Okita et al., 2007; Howe et al.,
2008)
Possible preservation Tumourogenesis (Okita et al., 2007).
Availability and accessability of source cells Chances of development of diseases due to factors used
(Ghaleb et al., 2005; Hochedlinger et al., 2005; Kuttler and
Mai, 2006; Park et al., 2008c)
Personalization of treatment (Chun et al., 2011) Suboptimal standardization (Pappas and Yang, 2008)
Applications High-throughput screening of drugs and toxicity prediction
(Wobus and Loser, 2011; Choi et al., 2013)
Complex assessment
Reduced cost Complex diseases become difficult to be modeled
Gene correction therapies add to the benefits from iPSCs
(Choi et al., 2013)
Immature cells cause problems during cell line
development
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collection of sample would be carried out in an ethical way. After
the collection and culture of the source cell, a suitable reprogram-
ming method is to be decided. The use of retroviral vectors has
risks of insertional mutagenesis and hence their use is not ideal
for clinical applications. Non-viral methods address this question
and the method is chosen according to pros and cons associated.
Once the iPSCs have generated, proper characterization is vitally
required. For the verification that the iPSCs generated are really
pluripotent, the expression of different pluripotency markers is
assessed. It must be checked if the iPSCs generated can differ-
entiate to all the three germ layers. To further check the ability
of the iPSCs to differentiate, the efficiency of generation of the
cells which are required for the therapy is determined. The cells
generated must be tested to be functional, so the physiological
properties of cells generated from iPSCs were compared with that
of the cells generated from ESCs. The final product has variabil-
ity which depends on the quality of starting material used as cell
source, difference in other raw materials used for cell culture, and
the protocol followed. Identifying and controlling these is impor-
tant to standardize any manufacturing process to demonstrate
reproducibility and consistent production meeting the specifica-
tions. Research based methods that have manual nature may not
prove to be ideal for the large production of cells. Quality con-
trol testing for final product and preparation procedures must
also be designed. For administration of fresh cells, there is need
of a rapid method for detection of contamination. Plans must
be there in case if the sample fails the sterility test, if the patient
has already been administered with the product. Once the quality
testing has been done, it should be ensured that the final cell ther-
apeutic is meeting all the required specifications. For allogeneic
therapies, a cell bank must be established which would contain
the starting cell material and it should be tested to check the con-
sistency of that material. Establishment of a large cell bank is
not important for autologous therapeutics; a small bank would
serve the purpose of identification and minimization of vari-
ability that may result from initial reprogramming. The colonies
which meet the specifications of karyotype, marker expression,
mycoplasma/bacterial/fungal contaminate and growth character-
istics, are expanded to build a bank. Additional knowledge about
the post release handling of the cell product is also required.
It is important to ensure that the final cell product is repre-
sentative of therapeutic that will be subjected to human clinical
trials. Preclinical animal studies should be able to address the
safety of the cell product which includes the affects of the con-
taminants present in the cell population from donor, chances
of teratoma formation and generation of karyotypically unstable
cells. It should be ensured that the changes in process associated
with change from animal studies to production for clinical use
would not cause any significant problems.
FUTURE PERSPECTIVES
Since the emergence of the field of iPSCs, it has highly devel-
oped and successfully expanded to different fields of regenerative
medicine. Their application in clinical research will surely bene-
fit the patients in future. At present there are few, but important
applications of iPSCs but, if this field keeps on growing at the
present pace, it wouldn’t take long to expand the applications of
iPSCs to more biological fields to aid research and treatments.
iPSCs are important in disease modeling as they do not have eth-
ical issues concerned as in case of ESCs and provide with the
physiological conditions more close to humans which is not an
advantage with the animal disease models. iPSCs also have a pos-
sibility of giving consistent phenotypes every time, which is an
important issue for disease modeling. More and more types of
diseased cells are being tried to be modeled, but, it still has many
limitations that are encountered while working with iPSCs, which
need to be overcome. Also, it is not possible to be able to model
every disease, so, further exploration of modeling diseases with
iPSCs is required. As iPSCs eliminate the chances of immunore-
jection, they hold great importance in Gene therapy. But the
generation of iPSCS itself has many issues associated it like incor-
poration of vectors into host genomes, and the dependence on
the various factors like usage of small molecules, single or mul-
tiple vectors, source of cells, which make the generation of iPSCs
a risky task and hence, more about iPSCs need to be explored to
make it easier to generate them and to be able to apply them to
various other important and attractive areas of medical sciences
for their proper utilization to achieve the advantages that use of
iPSCs can have. And, different advances in the field, including the
solution of many limitations mentioned above would prove to be
beneficial for increasing therapeutic potential. The present situa-
tion of the applications of iPSCs deals with the laboratory scale
production and testing assay. A lot has to be done to realize the
applications of iPSCs at a higher level, for the use in hospitals, to
be beneficial for the patients.
CONCLUSION
The iPSC therapy is in infancy but a constant progress in repro-
gramming technologies has occurred; new and improved meth-
ods are gathering. As iPSCs can differentiate to different cell
types, we can generate the required cells for the study or treat-
ment of numerous diseases and determination of drug toxicity.
The therapy using HSCs is being used since a long time. The
change from allogeneic to autologous iPSCs has been a major
breakthrough. Autologous therapy also offers the advantage of
personalized medicine.
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